Novanta Rides GPU Drilling Monopoly and Broad Bookings Surge Into 2026, But Margin Miss Clouds an Otherwise Strong Quarter
Q4 2025 Earnings Call — February 24, 2026
Novanta entered 2026 with its strongest bookings momentum since 2022 and an unexpected new growth engine in artificial intelligence infrastructure, but the quarter ended with a self-inflicted margin shortfall that management was quick to own. The company posted record Q4 revenue of approximately $260 million, with 9% reported growth and 2% organic growth, while adjusted EBITDA expanded 17% year-over-year. Yet adjusted gross margins came in at 45.5%, down 150 basis points year-over-year and below the guidance set just three months earlier, a miss driven entirely by the decision to prioritize customer deliveries over the pace of regional manufacturing transfers. That single operational call created over 100 basis points of dual-running cost drag and pushed net working capital up 400 basis points as a percent of sales. Management moved to correct course in January and is guiding for sequential gross margin improvement in Q1, with the full transfer completed by end of Q2.
The GPU Drilling Revelation: A Monopoly Position Nobody Was Talking About
The most significant new disclosure on the call was Novanta's sole-source position in drilling GPU boards for artificial intelligence compute infrastructure. The company's air bearing spindles are currently the only qualified supplier for this application, and the business is growing at a strong double-digit rate. CEO Matthijs Glastra was unambiguous: "It became clear that the leader in GPUs had a personal interest in this in terms of scaling that." The technical logic is straightforward — GPU boards are getting thicker and are made of increasingly demanding materials, and the throughput and precision requirements can only be met at scale by Novanta's spindles. Glastra described a "multiyear trajectory" and noted the company sees this as a leadership position it has always held in drilling precision boards, now being applied to a dramatically faster-growing end market. The customer relationships here are with established OEM equipment makers that Novanta has worked with for decades; the new element is the end-user demand coming from hyperscale AI infrastructure buildout. Investors should treat this as a genuinely new and material data point — it was not part of the prior narrative.
Bookings Surge Is Broad-Based, Not a Single-Segment Story
For the first time since 2022, every single business unit delivered double-digit bookings growth and a positive book-to-bill in the same quarter. Company-wide bookings grew 25% year-over-year and 12% sequentially, with a consolidated book-to-bill of 1.11. CFO Robert Buckley provided granular data during the Q&A that underscores the depth of this inflection: Precision Manufacturing had a book-to-bill of 1.20 with nearly 50% bookings growth and a backlog of just over $100 million, roughly 2x quarterly revenue. Robotics and Automation had a book-to-bill of 1.13 with close to 25% bookings growth and a backlog at approximately 1.5x quarterly revenue. Advanced Surgery posted a 1.12 book-to-bill with close to 15% bookings growth and a backlog of roughly 2x quarterly revenue. Precision Medicine had a 1.01 book-to-bill with 22% bookings growth and a backlog near 2x quarterly revenue. Buckley was direct about what this means: "This is strong empirical evidence that our organic growth outlook for 2026 is demand driven and not aspirational."
Three Distinct AI-Driven Tailwinds in Robotics and Automation
Management articulated three structurally distinct growth drivers for the Robotics and Automation business that are worth separating in investors' minds. First is physical AI — Novanta's force/torque sensors and servo drives enable perception and precise motion control in end-of-arm robotics across warehouse automation, surgical robotics, and humanoids. Buckley noted the company is working with standards bodies including ISO to help define how robots operate safely in manufacturing and home environments, and characterized the competitive position in servo drives and force/torque technology as "really superior to anything out there." Second is a recovering semiconductor wafer fab equipment cycle, where early signs of an upcycle are translating into bookings momentum. Third is the GPU drilling opportunity described above. Together, management is guiding for high single-digit growth in this business in 2026.
Advanced Surgery Remains the Standout, With a Long Runway
The Medical Solutions segment grew 16% in Q4 on a reported basis, with Advanced Surgery up 15% for the year. The second-generation insufflator platform continues to see strong OEM demand, and the attached medical consumables business — now 15% of total company revenue — is growing at double-digit rates with high attachment rates to the new insufflator. Management is targeting approximately $400 million in Advanced Surgery revenue by 2030, roughly double current levels, driven by the insufflation franchise, expansion into robotic surgery and arthroscopy, and consumables scale. The book-to-bill of 1.12 in this segment and a backlog of 2x quarterly revenue provide solid near-term visibility. The strategic framing is also notable: Novanta views its relationships with major surgical OEM customers as a platform to cross-sell additional subsystems, and the M&A pipeline is explicitly oriented toward adjacent medtech categories that serve the same customer base.
Precision Manufacturing Finally Turning: Four Quarters of Double-Digit Bookings Now Translating to Revenue
After two years of customer destocking headwinds, the Precision Manufacturing business is showing concrete inflection. Four consecutive quarters of double-digit bookings growth culminated in 8% sequential revenue growth in Q4, and management is guiding for mid-single-digit growth in 2026. The convergence of destocking completion, design win ramp, and new intelligent laser beam steering subsystem launches — which Glastra described as achieving "2x to 5x better" performance than existing market alternatives by combining proprietary hardware and embedded software — is expected to drive sequential revenue acceleration through the year. The reshoring dynamic adds an additional layer: manufacturers offsetting productivity losses from supply chain localization are turning to Novanta's precision and throughput capabilities.
Full Year 2026 Guidance: Margin Recovery Back-Half Loaded, EPS Headwinds Are Temporary
Novanta guided full year 2026 revenue of $1.03 billion to $1.05 billion, representing 4% to 6% organic growth. The organic growth profile is explicitly front-back weighted: Q1 at positive 1% to 3%, Q2 stepping up to positive 5% to 7%, with similar growth levels in the back half. Full year adjusted EBITDA guidance of $245 million to $250 million implies approximately 24% margins, up roughly 100 basis points from 2025, with the expansion driven by completion of the regional manufacturing transfers in Q2. Adjusted EPS guidance of $3.50 to $3.65 implies up to 11% growth, but investors should understand the embedded headwinds: the November equity raise creates a $0.22 to $0.24 per share drag from the higher share count, and the 2025 all-employee equity grant creates a $0.14 first-half-only headwind. Stripping those out, the underlying operational EPS growth is considerably higher than the headline figure suggests. Operating cash flow is guided to $145 million to $185 million, more than double 2025's $64 million result, with the range reflecting inventory risk around the manufacturing moves.
$1.5 Billion Acquisition Capacity, Largest Pipeline in CEO's Tenure
The November equity raise of over $600 million was explicitly designed to fund M&A, and Glastra stated plainly that the acquisition pipeline is "the largest in my tenure as CEO." The strategic focus is on mid-to-larger transactions in medical technologies, medical consumables, bioprocessing, and embedded software-hardware subsystems. Buckley laid out the financial discipline clearly: targets must exceed cost of capital by year two for bolt-ons and year five for larger deals, must carry gross margins of 50% or above, and must be free cash flow accretive from day one with cash conversion ratios above Novanta's own. The company is explicitly not looking to lever above 3x to 3.5x. Glastra's framing of the embedded software opportunity is important context for evaluating targets: the company is not interested in application-layer software, but rather in hardware-software combinations where embedded algorithms and firmware are intrinsic to proprietary subsystem functionality — a distinction with significant implications for competitive moat and valuation discipline.
Keonn Acquisition Already Ahead of Plan, Hospital Market Beta Testing Underway
The Keonn RFID acquisition, which added approximately $9 million of Q4 revenue, is already outperforming its deal model and is expected to do so again in 2026. Buckley described a business model with both project-based revenue and a recurring software subscription stream: Keonn owns and controls the data gathered from its RFID readers and sells it to customers through a recurring revenue arrangement, with customers then applying analytics or AI tools on top. The strategic rationale — applying intelligent RFID to hospital asset tracking and patient safety — remains intact, and Novanta made a small minority investment in a Spanish company with hospital access to begin beta testing the medical application. The regulatory complexity around data and patient privacy in healthcare settings is acknowledged, but the company is moving methodically to understand the go-to-market requirements before scaling.
Manufacturing Transfer Overhang: Real, but Management Has a Credible Fix
The Q4 gross margin miss deserves scrutiny. Novanta chose to run dual manufacturing facilities simultaneously rather than pause customer deliveries during regional transfers — a defensible customer-first decision, but one that cost more than 100 basis points of gross margin and created a significant inventory build. Operating cash flow for the full quarter was just $9 million against $62 million in the prior year period. Management's recovery thesis rests on transfer completion by end of Q2 and inventory drawdown in the first half. Q1 gross margin guidance of approximately 46.5% represents a sequential step up, and the full year target of 47% requires a more meaningful expansion in the back half. If the transfer timeline slips again, the margin recovery thesis faces risk. For now, the company's credibility rests on whether January's corrective actions, which management says have already been implemented, hold through the first half.
Novanta Deep Dive
The Business Model and Revenue Engine
Novanta operates as a highly specialized, Tier-1 supplier of mission-critical subsystems to original equipment manufacturers in the medical and advanced industrial sectors. The overarching business model is predicated on a "design-in" strategy. Rather than selling commoditized, off-the-shelf components, Novanta engineers deeply integrated solutions encompassing precision photonics, vision technology, and motion control. These subassemblies typically account for less than ten percent of the customer's total bill of materials but are fundamentally responsible for the end-product's defining performance characteristics, such as the exactness of a surgical robotic arm or the throughput of a DNA sequencing machine.
The company generates its revenue—which reached a record $981 million in the 2025 fiscal year—through two primary reporting segments: Medical Solutions and Automation Enabling Technologies. The Medical Solutions segment, representing approximately 53 percent of total sales, provides customized technologies for advanced surgery and precision medicine. Its offerings include medical-grade insufflators, surgical visualization systems, radio-frequency identification technologies for consumable tracking, and embedded touchscreens. The Automation Enabling Technologies segment, accounting for the remaining 47 percent, serves the robotics, automation, and precision manufacturing end-markets. This division supplies highly engineered lasers, optical and inductive encoders, precision motors, servo drives, air bearings, and robotic end-of-arm tooling.
By positioning itself as an outsourced engineering partner rather than a simple parts distributor, Novanta locks in recurring, long-tail revenue streams. A typical product lifecycle for an original equipment manufacturer in the medical or industrial space spans seven to ten years. Once a Novanta subsystem is engineered into a platform, the company captures steady, predictable volume throughout that platform's lifespan. Furthermore, Novanta has increasingly pushed into medical consumables and embedded software, effectively shifting its revenue mix to include higher-margin, recurring income alongside its traditional capital equipment component sales.
Customers, Competitors, and Supply Chain
Novanta's customer base consists of the world's largest and most sophisticated equipment manufacturers. In the medical space, the company works alongside titans of robotic surgery and life sciences. While Novanta often operates behind non-disclosure agreements regarding specific platform integrations, its optical and precision motion architectures are widely utilized in systems produced by robotic surgery leaders like Intuitive Surgical, as well as life science heavyweights such as Illumina and Thermo Fisher Scientific. In the advanced industrial segment, its customers include major semiconductor lithography manufacturers and warehouse automation integrators. These customers demand micron-level precision, near-zero failure rates, and rigorous regulatory compliance, effectively narrowing the pool of capable suppliers.
Because Novanta operates at the intersection of photonics, vision, and motion, its competitive landscape is fragmented across highly specialized domains. In the photonics and laser segments, Novanta competes against formidable pure-play firms like IPG Photonics, Coherent, and Lumentum. In the precision motion space, it faces industrial heavyweights such as Parker Hannifin, Allied Motion, and Maxon Motor. In machine vision, competitors include Cognex and Teledyne. However, Novanta circumvents direct, commoditized competition by offering integrated sub-systems. Instead of a customer buying a laser from Coherent and a motor from Maxon to build a scanning head internally, Novanta provides the fully integrated, software-enabled laser-and-motion module. This reduces the manufacturer's time-to-market and supply chain complexity.
The company's supply chain is relatively insulated from exotic raw material constraints. Novanta procures standard electronic components, specialized metals, and optics from a globally diversified supplier base. The true value generation lies not in the scarcity of the raw inputs, but in the intellectual property, precision machining, and clean-room assembly processes required to synthesize these inputs into complex, high-performance subassemblies. In response to recent geopolitical tensions, the company has actively regionalized its manufacturing footprints in China and Southeast Asia, a strategic move designed to shorten lead times and hedge against trans-Pacific trade disruptions.
Market Share and Competitive Moat
While Novanta holds a modest share of the broad, multitrillion-dollar industrial component market, it wields dominant, oligopolistic market share in highly targeted niches. For instance, Novanta is recognized as a top-three global provider of surgical carbon dioxide lasers and high-performance scanning heads utilized in ophthalmology and genetic sequencing. In the specialized realm of integrated medical motion, industry estimates suggest the company commands a market share nearing 20 percent, backed by extreme barriers to entry.
The primary competitive moat safeguarding Novanta's market position is the prohibitive switching cost inherent in regulated industries. In the medical technology sector, original equipment manufacturers are subject to stringent oversight by the Food and Drug Administration and the European Medicines Agency. Substituting a critical component—such as the vision system in a surgical laparoscope or the precision encoder in a robotic arm—requires the manufacturer to effectively redesign the subassembly and undergo a grueling, expensive re-validation process. Consequently, unless Novanta's components fail to meet quality standards, customers are highly disincentivized from seeking alternative suppliers to save marginal amounts on their bill of materials.
This structural advantage is fortified by a formidable intellectual property portfolio. Novanta holds over 2,000 patents and deploys an outsized 10 to 12 percent of its annual revenue toward research and development. With approximately 650 engineers on staff, Novanta maintains a deep well of proprietary technical expertise that broad-based industrial conglomerates struggle to replicate without undertaking highly dilutive acquisitions. This innovation intensity is reflected in the company's vitality index, with new product sales recently growing to represent 22 percent of total revenue.
Industry Dynamics: Opportunities and Threats
Novanta is strategically positioned to capitalize on several durable macroeconomic megatrends. The foremost opportunity lies in the proliferation of minimally invasive and robotic-assisted surgery. As global healthcare systems seek to reduce hospital stay durations and improve clinical outcomes, the surgical robotics end market is projected to expand at a compound annual growth rate exceeding 15 percent through the end of the decade. Novanta's ability to supply the critical "eyes and muscles" for these robotic platforms provides a clear secular tailwind. Additionally, the near-shoring of semiconductor manufacturing and the rapid automation of warehouse logistics present highly lucrative avenues for Novanta's advanced industrial motion and machine vision segments.
However, the industry is not without material threats. Novanta is highly exposed to the capital expenditure cycles of its end markets. The life sciences and biotechnology sectors periodically digest pandemic-era capacity expansions, which can lead to abrupt decelerations in demand for DNA sequencing and diagnostic instrumentation hardware. Similarly, the semiconductor equipment market is notoriously cyclical. Furthermore, as Novanta transitions its operations to regional manufacturing hubs to de-risk its supply chain, it has incurred dual-running costs that have temporarily compressed gross margins and weighed on working capital. While management views these pressures as transient, any prolonged disruption in these facility transfers could erode profitability.
Innovation Engine and Next-Generation Drivers
Novanta's research and development engine is aggressively pivoting toward intelligent subsystems. The traditional hardware paradigms are being augmented by embedded software and edge artificial intelligence. A prime example is the company's development of AI-enhanced smoke evacuation systems for smart operating rooms, which dynamically adjust suction based on real-time visual analysis of the surgical field. Furthermore, Novanta is heavily investing in physical AI applications designed for humanoid robotics and advanced warehouse automation. By embedding predictive maintenance algorithms directly onto its motor drives and laser heads, Novanta is transforming passive hardware into active, self-calibrating systems that drastically reduce end-user downtime.
The company is also unlocking high-growth adjacent markets. In the industrial sector, Novanta is adapting its high-power laser scanning technologies for precision welding applications in electric vehicle battery manufacturing, a high-margin niche demanding exact tolerances. In the medical sector, the 2025 acquisition of Keonn Technologies has bolstered Novanta's capabilities in advanced radio-frequency identification. This technology is being integrated into medical solutions to track surgical consumables and automate hospital inventory management. The strategic push into medical consumables—which now account for roughly 15 percent of total sales and are growing at a double-digit rate—serves to smooth out the cyclicality of its capital equipment revenues.
In analyzing potential disruptors, the most credible threat from new entrants stems from software-native technology firms. These challengers are developing sophisticated, cloud-based computer vision analytics that can theoretically operate on cheaper, commoditized optical hardware. If complex optical processing can be offloaded to the cloud or managed entirely by advanced machine learning models utilizing lower-grade lenses and sensors, it could commoditize the specialized, high-end vision hardware that Novanta produces. To date, latency requirements and the strict regulatory environment in surgery have kept cloud-reliant systems at bay, but edge-AI native startups represent an evolving vector of competition.
Management and Track Record
The executive leadership, guided by Chief Executive Officer Matthijs Glastra, has orchestrated one of the most successful corporate turnarounds in the industrial technology sector. Following its emergence from Chapter 11 bankruptcy as GSI Group in 2010, the company was fundamentally repositioned. Glastra, drawing upon his extensive tenure at Danaher Corporation, instilled a culture of continuous improvement known as the Novanta Growth System. Under his stewardship since 2016, management deliberately pivoted away from volatile legacy businesses, divesting non-core assets and utilizing the proceeds to aggressively expand into high-margin medical and advanced industrial markets.
The management team's capital allocation track record is highly disciplined and systematic. Over the past decade, Novanta has executed over twenty strategic acquisitions, deploying more than $1.2 billion to acquire niche technology leaders like Celera Motion, ATI Industrial Automation, and Motion Solutions. Rather than pursuing empire-building, these deals have been calculated tuck-ins designed to acquire specific technological capabilities and engineer fully integrated subsystems. In late 2025, management demonstrated significant foresight by raising over $600 million in equity capital, establishing an acquisition war chest of approximately $1.5 billion. While prioritizing customer deliveries over regional transfer timing in 2025 resulted in short-term margin compression, the leadership team's long-term operational credibility remains intact, evidenced by a book-to-bill ratio firmly above 1.0 and a staggering 25 percent year-over-year surge in fourth-quarter bookings.
The Scorecard
Novanta presents a compelling case study in the power of extreme specialization and deep customer integration. By eschewing commoditized component markets in favor of engineering mission-critical, highly regulated subsystems, the company has erected substantial switching costs that protect its revenue base. The strategic application of the Novanta Growth System, coupled with a highly disciplined, programmatic acquisition strategy, has allowed the company to compound value effectively while expanding its total addressable market into the secular growth vectors of robotic surgery, precision medicine, and digital manufacturing.
The principal risks lie in the cyclical capital expenditure dynamics of its underlying life science and semiconductor end markets, as well as the immediate execution risk tied to wrapping up its global manufacturing footprint transition. The potential commoditization of hardware by software-native entrants is an ambient, long-tail threat. However, Novanta's proactive investments in edge artificial intelligence and its successful pivot toward higher-margin medical consumables demonstrate a highly adaptive management team capable of navigating these headwinds. Ultimately, the company's entrenched position within the supply chains of the world's most dominant healthcare and industrial automation platforms forms an exceptionally resilient structural foundation.